


NLRP3-IN-24

Cat. No.:	HY-157147
Molecular Formula:	C ₁₉ H ₂₆ O ₃ Si
Molecular Weight:	330.49
Target:	TNF Receptor; Interleukin Related
Pathway:	Apoptosis; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	NLRP3-IN-24 (Compound 15a) is an inhibitor against NLRP3. NLRP3-IN-24 has an inhibitory effect on the activation of NLRP3 inflammasome ^[1] .									
IC₅₀ & Target	IL-6	IL-1β								
In Vitro	<p>NLRP3-IN-24 (0.1-10 μM, 1 h) inhibits the activity against heme-induced NLRP3 mediated inflammation in THP-1 cells and J774A.1 cells^[1].</p> <p>NLRP3-IN-24 (10 μM, 24 h) is nontoxic in J774A.1 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>J774A.1 cells</td> </tr> <tr> <td>Concentration:</td> <td>10.0 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Showed nontoxic in J774A.1 cells at 10 μM</td> </tr> </table>		Cell Line:	J774A.1 cells	Concentration:	10.0 μM	Incubation Time:	24 h	Result:	Showed nontoxic in J774A.1 cells at 10 μM
Cell Line:	J774A.1 cells									
Concentration:	10.0 μM									
Incubation Time:	24 h									
Result:	Showed nontoxic in J774A.1 cells at 10 μM									
In Vivo	<p>NLRP3-IN-24 (10-30 mg/kg, Intraperitoneal injection, 30 min before the administration of LPS, single dose) inhibits the activation of NLRP3 inflammasome in peritoneal inflammation model^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Peritoneal inflammation model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg, 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection (i.p.)</td> </tr> <tr> <td>Result:</td> <td>Significant decreased the levels of IL-1β.</td> </tr> </table>		Animal Model:	Peritoneal inflammation model ^[1]	Dosage:	10 mg/kg, 30 mg/kg	Administration:	Intraperitoneal injection (i.p.)	Result:	Significant decreased the levels of IL-1β.
Animal Model:	Peritoneal inflammation model ^[1]									
Dosage:	10 mg/kg, 30 mg/kg									
Administration:	Intraperitoneal injection (i.p.)									
Result:	Significant decreased the levels of IL-1β.									

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA